Accès gratuit
Numéro
Réanimation
Volume 25, Juillet 2016
Médecine interne et transversalité
Page(s) S123 - S136
Section Mise au Point / Update
DOI https://doi.org/10.1007/s13546-015-1161-4
Publié en ligne 1 mars 2016
  • Vogelzang NJ, Benowitz SI, Adams S, et al (2012) Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 30:88–109 [CrossRef] [PubMed] [Google Scholar]
  • Albini A, Pennesi G, Donatelli F, et al (2010). Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14–25 [CrossRef] [PubMed] [Google Scholar]
  • Azoulay E, Mokart D, Pène F, et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–8 [CrossRef] [PubMed] [Google Scholar]
  • Berardi R, Caramanti M, Savini A, et al (2013) State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 88:75–86 [CrossRef] [PubMed] [Google Scholar]
  • Senkus E, Jassem J (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37:300–11 [CrossRef] [PubMed] [Google Scholar]
  • Curigliano G, Mayer EL, Burstein HJ, et al (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94–104 [CrossRef] [PubMed] [Google Scholar]
  • Seidman A, Hudis C, Pierri MK, et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–21 [CrossRef] [PubMed] [Google Scholar]
  • Wu MY, Liu KS, Lin PJ, et al (2009) Resuscitation of acute anthracycline-induced cardiogenic shock and refractory hypoxemia with mechanical circulatory supports: pitfalls and strategies. Resuscitation 80:385–6 [Google Scholar]
  • Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–47 [CrossRef] [PubMed] [Google Scholar]
  • Isner JM, Ferrans VJ, Cohen SR, et al (1983) Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 51:1167–74 [CrossRef] [PubMed] [Google Scholar]
  • Elliott P (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33:S2–S7 [CrossRef] [PubMed] [Google Scholar]
  • Mackay B, Ewer MS, Carrasco CH, Benjamin RS (1994) Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203–11 [CrossRef] [PubMed] [Google Scholar]
  • Ali MK, Ewer MS, Gibbs HR, et al (1994) Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer 74:182–8 [CrossRef] [PubMed] [Google Scholar]
  • Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2 [CrossRef] [PubMed] [Google Scholar]
  • Ewer MS, Vooletich MT, Durand J-B, et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820–6 [CrossRef] [PubMed] [Google Scholar]
  • Von Hoff DD, Layard MW, Basa P, et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–7 [CrossRef] [PubMed] [Google Scholar]
  • Wouters KA, Kremer LCM, Miller TL, et al (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–78 [CrossRef] [PubMed] [Google Scholar]
  • Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–79 [CrossRef] [PubMed] [Google Scholar]
  • Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302 [CrossRef] [PubMed] [Google Scholar]
  • Altena R, Perik PJ, van Veldhuisen DJ, et al (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391–9 [CrossRef] [PubMed] [Google Scholar]
  • Braverman AC, Antin JH, Plappert MT, et al (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–23 [PubMed] [Google Scholar]
  • Kupari M, Volin L, Suokas A, et al (1990) Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 5:91–8 [PubMed] [Google Scholar]
  • Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4:235–42 [CrossRef] [PubMed] [Google Scholar]
  • Guarneri V, Lenihan DJ, Valero V, et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107–15 [CrossRef] [PubMed] [Google Scholar]
  • Wadhwa D, Fallah-Rad N, Grenier D, et al (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 117:357–64 [CrossRef] [PubMed] [Google Scholar]
  • Chen MH, Kerkelä R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84–95 [CrossRef] [PubMed] [Google Scholar]
  • Kerkelä R, Grazette L, Yacobi R, et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–16 [CrossRef] [PubMed] [Google Scholar]
  • Chu TF, Rupnick MA, Kerkela R, et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet Lond Engl 370:2011–9 [CrossRef] [PubMed] [Google Scholar]
  • Perez EA, Koehler M, Byrne J, et al (2008) Cardiac safety of lapatinib: pooled analysis of 3,689 patients enrolled in clinical trials. Mayo Clin Proc 83:679–86 [CrossRef] [PubMed] [Google Scholar]
  • de Forni M, Malet-Martino MC, Jaillais P, et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801 [PubMed] [Google Scholar]
  • Jensen SA, Sørensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–93 [CrossRef] [PubMed] [Google Scholar]
  • Meyer CC, Calis KA, Burke LB, et al (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17:729–36 [PubMed] [Google Scholar]
  • Lejonc JL, Vernant JP, Macquin J, Castaigne A (1980) Myocardial infarction following vinblastine treatment. Lancet Lond Engl 2:692 [CrossRef] [Google Scholar]
  • Rowinsky EK, McGuire WP, Guarnieri T, et al (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704–12 [PubMed] [Google Scholar]
  • Meinardi MT, Gietema JA, van der Graaf WT, et al (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–32 [PubMed] [Google Scholar]
  • Escudier B, Eisen T, Stadler WM, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–34 [CrossRef] [PubMed] [Google Scholar]
  • Quezado ZM, Wilson WH, Cunnion RE, et al (1993) High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31–6 [CrossRef] [PubMed] [Google Scholar]
  • Ng M, Cunningham D, Norman AR (2005) The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41:1542–6 [CrossRef] [PubMed] [Google Scholar]
  • Guzzetti S, Costantino G, Fundarò C (2002) Systemic inflammation, atrial fibrillation, and cancer. Circulation 106:e40 [CrossRef] [PubMed] [Google Scholar]
  • van der Hooft CS, Heeringa J, van Herpen G, et al (2004) Drug-induced atrial fibrillation. J Am Coll Cardiol 44:2117–24 [CrossRef] [PubMed] [Google Scholar]
  • Rowinsky EK, Eisenhauer EA, Chaudhry V, et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15 [Google Scholar]
  • Arbuck SG, Strauss H, Rowinsky E, et al (1993) A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 15:117–130 [PubMed] [Google Scholar]
  • Clark TE, Edom N, Larson J, Lindsey LJ (2001) Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 24:87–117 [CrossRef] [PubMed] [Google Scholar]
  • Kaur A, Yu SS, Lee AJ, Chiao TB (2003) Thalidomide-induced sinus bradycardia. Ann Pharmacother 37:1040–3 [CrossRef] [PubMed] [Google Scholar]
  • Yusuf SW, Razeghi P, Yeh ETH (2008) The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33:163–96 [CrossRef] [PubMed] [Google Scholar]
  • Kantarjian H, Sawyers C, Hochhaus A, et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–52 [CrossRef] [PubMed] [Google Scholar]
  • Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–22 [CrossRef] [PubMed] [Google Scholar]
  • Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–50 [CrossRef] [PubMed] [Google Scholar]
  • Sack GH, Levin J, Bell WR (1977) Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1–37 [CrossRef] [PubMed] [Google Scholar]
  • Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72:43–52 [CrossRef] [PubMed] [Google Scholar]
  • Kakkar AK, Williamson RC (1999) Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:239–43 [CrossRef] [PubMed] [Google Scholar]
  • Thompson CM, Rodgers LR (1952) Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 223:469–78 [CrossRef] [PubMed] [Google Scholar]
  • Levine MN, Gent M, Hirsh J, et al (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404–7 [CrossRef] [PubMed] [Google Scholar]
  • Heit JA, Silverstein MD, Mohr DN, et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–15 [CrossRef] [PubMed] [Google Scholar]
  • Mitchell L, Hoogendoorn H, Giles AR, et al (1994) Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in l’asparaginase-induced antithrombin III deficiency. Blood 83:386–391 [PubMed] [Google Scholar]
  • Pritchard KI, Paterson AH, Fine S, et al (1997) Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 15:2302–11 [PubMed] [Google Scholar]
  • Hernandez RK, Sørensen HT, Pedersen L, et al (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115:4442–9 [CrossRef] [PubMed] [Google Scholar]
  • Kuenen BC, Levi M, Meijers JCM, et al (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21:2192–8 [CrossRef] [PubMed] [Google Scholar]
  • Nalluri SR, Chu D, Keresztes R, et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–85 [CrossRef] [PubMed] [Google Scholar]
  • Ryberg M (2013) Cardiovascular toxicities of biological therapies. Semin Oncol 40:168–77 [CrossRef] [PubMed] [Google Scholar]
  • Rajkumar SV, Blood E, Vesole D, et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–6 [CrossRef] [PubMed] [Google Scholar]
  • Palumbo A, Rajkumar SV, Dimopoulos MA, et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–23 [CrossRef] [PubMed] [Google Scholar]
  • Goyal G, Bhatt VR (2015) L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future Oncol 11:2459–70 [CrossRef] [PubMed] [Google Scholar]
  • Svendsen E, Karwinski B (1989) Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 42:805–9 [CrossRef] [PubMed] [Google Scholar]
  • Valade S, Lemiale V, Roux A, et al (2015) Life-threatening complications and outcomes in patients with malignancies and severe pulmonary embolism. Thromb Res 135:610–5 [CrossRef] [PubMed] [Google Scholar]
  • Farge D, Debourdeau P, Beckers M, et al (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11:56–70 [CrossRef] [PubMed] [Google Scholar]
  • Dahut WL, Gulley JL, Arlen PM, et al (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532–9 [CrossRef] [PubMed] [Google Scholar]
  • Zangari M, Fink LM, Elice F, et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865–73 [CrossRef] [PubMed] [Google Scholar]
  • Scappaticci FA, Skillings JR, Holden SN, et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–9 [CrossRef] [PubMed] [Google Scholar]
  • Macedo LT, da Costa Lima AB, Sasse AD (2012) Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:89 [CrossRef] [PubMed] [Google Scholar]
  • Lechner K, Obermeier HL (2012) Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 91:195–205 [CrossRef] [PubMed] [Google Scholar]
  • Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858–66 [CrossRef] [PubMed] [Google Scholar]
  • Zuber J, Martinez F, Droz D, et al (2002) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 81:321–331 [CrossRef] [PubMed] [Google Scholar]
  • Ponticelli C, Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 19:789–94 [Google Scholar]
  • Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–95 [CrossRef] [PubMed] [Google Scholar]
  • Kabbinavar FF, Schulz J, McCleod M, et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–705 [CrossRef] [PubMed] [Google Scholar]
  • Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18:1117 [CrossRef] [PubMed] [Google Scholar]
  • Wu S, Chen JJ, Kudelka A, et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117–23 [CrossRef] [PubMed] [Google Scholar]
  • Wadei HM, Textor SC (2010) Hypertension in the kidney transplant recipient. Transplant Rev 24:105–20 [CrossRef] [PubMed] [Google Scholar]
  • Hoorn EJ, Walsh SB, McCormick JA, et al (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25:269–75 [CrossRef] [PubMed] [Google Scholar]
  • Sambasivan K, Mahmoud S, Kokache A, et al (2014) Hypersensitivity reactions to etoposide phosphate. J Oncol Pharm Pract 20:158–60 [CrossRef] [PubMed] [Google Scholar]
  • Yeh ETH (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57:485–98 [CrossRef] [PubMed] [Google Scholar]
  • Schimmel KJM, Richel DJ, van den Brink RBA, Guchelaar HJ (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–91 [CrossRef] [PubMed] [Google Scholar]
  • Floyd JD, Nguyen DT, Lobins RL, et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685–96 [CrossRef] [PubMed] [Google Scholar]
  • Slørdal L, Spigset O (2006) Heart failure induced by non-cardiac drugs. Drug Saf 29:567–86 [CrossRef] [PubMed] [Google Scholar]
  • Wohlfarth P, Staudinger T, Sperr WR, et al (2014) Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol 93:1629–36 [CrossRef] [PubMed] [Google Scholar]
  • Song JU, Suh GY, Chung MP, et al (2011) Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer 19:491–5 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Thiery G, Ciroldi M, et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–93 [CrossRef] [PubMed] [Google Scholar]
  • Collins C, Weiden PL (1987) Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 71:733–6 [PubMed] [Google Scholar]
  • Tallaj JA, Franco V, Rayburn BK, et al (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196–201 [CrossRef] [PubMed] [Google Scholar]
  • Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–10 [CrossRef] [PubMed] [Google Scholar]
  • Maitland ML, Bakris GL, Black HR, et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.